Glioblastoma and DIPG are among the deadliest brain cancers, often taking lives in under two years—but a breakthrough treatment may finally offer real hope. Our new drug, GCT-007, has shown unprecedented results in pre-clinical studies, including complete tumor elimination in 30% of cases. Top institutions like Mayo Clinic and Barrow are backing it with their own funds, recognizing its potential to transform brain cancer treatment. But without immediate funding, this life-saving innovation could vanish in the “Valley of Death” that kills too many promising cancer therapies. We can’t afford to lose this chance—not when lives are on the line.
SHARE:
Glioblastoma and DIPG are the deadliest forms of brain cancer, often taking lives in less than two years despite aggressive treatment. The reality is heartbreaking, and for far too long, progress has been painfully slow.
But a new wave of innovation is offering hope.
Over the past decade, cancer immunotherapy—where we empower the body’s own immune system to fight cancer—has changed the game for diseases like melanoma and lung cancer. Unfortunately, it hasn’t worked well for brain cancer… yet. That’s because GBM and DIPG create a highly resistant environment, blocking immune cells from doing their job.
At Global Cancer Technology, we’re working on something that could transform how we treat brain cancer.
Our team has developed a powerful new compound, GTC-007, designed to do what few therapies can: reach the brain, shut down tumor growth, and awaken the body’s immune system to fight back.
This innovative drug not only crosses the blood-brain barrier—a major hurdle in brain cancer treatment—but also helps the immune system recognize cancer more clearly. It slows cancer cell growth, makes tumors more sensitive to radiation, and helps restore the body’s ability to defend itself.
In short: it fights smarter, not harder.
This isn’t just a new medicine—it’s a new way of thinking about brain cancer. And we believe it could be a turning point for thousands of patients and families looking for hope.
We’re preparing to complete our final pre-clinical studies in order to move into a Phase 1 clinical trial—an exciting and critical next step. So far, our pre-clinical results have been incredibly promising, especially in glioblastoma and DIPG, two of the most aggressive and deadly brain cancers.
Here’s what we’ve achieved so far:
Complete tumor elimination in 30% of subjects using our drug, GCT-007, combined with a checkpoint inhibitor. This result, seen in animal models, is unprecedented in glioblastoma research.
We were the first company to test and patent this unique combination approach, and it’s now drawing attention as more companies explore similar strategies.
Our treatment also successfully transformed “cold” tumors into “hot” tumors, meaning it helps the immune system recognize and fight cancer more effectively—a major breakthrough.
In head-to-head comparisons, GCT-007 outperformed Paxalisib, a competing drug currently in Phase 3 clinical trials. That’s a strong sign of our drug’s potential—and a powerful signal to early supporters that we’re on a promising path.
We’re focused on a critical next phase in our development journey. Funds raised will be dedicated to the following:
Completing pre-clinical studies in collaboration with our university research partners to further validate our drug’s safety and effectiveness.
Conducting formal toxicology studies that meet strict FDA guidelines (GLP-compliant), which are required to demonstrate safety before human trials can begin.
Engaging seasoned regulatory experts to guide us through the complex process of preparing and submitting our Investigational New Drug (IND) application to the FDA.
These steps are essential to launching our first-in-human clinical trial and ultimately bringing our breakthrough treatment to the patients who need it most.
We’ve built a strong foundation of support with nearly 200 investors, including many physicians who recognize the unique promise of our approach. To date, we’ve raised $1.5 million through a private investor program, connecting directly with supporters—many through our 30,000+ LinkedIn network—without the need for public advertising.
One of the biggest validations of our work comes from our research partners. Every university and medical institution that has studied our lead drug, GCT-007, has chosen to invest their own research dollars—a powerful sign of confidence in our science. These esteemed partners are not only impressed by our results—they continue to conduct more studies with us. Our collaborators include:
Brown University – Pediatric Glioblastoma/DIPG
Barrow Neurological Institute – Completed cell and animal studies
Baylor Scott & White – Phase I clinical trial site
Baylor College of Medicine (Waco & Houston) – Breast cancer & spontaneous GBM studies
Mayo Clinic – Pediatric GBM/DIPG
Moffitt Cancer Center – Radiation sensitivity studies
Medical College of Wisconsin – Final pre-clinical testing
University of Colorado Anschutz – Breast cancer models
University of Louisiana-Monroe – Psoriasis studies
University of Newcastle (Australia) – Drug comparison trials with Paxalisib
We’re also growing our leadership team with top industry talent. Most recently, we welcomed Dr. Sanjeev Thohan as our Chief Development Officer. Dr. Thohan brings deep experience, having advanced 42 drug candidates from pre-clinical research into human trials—and played key roles in securing major funding for those companies.
If this technology disappears in the Valley of Death, it’s not just a loss-it’s a tragedy.
GCT-007 has shown unheard-of results in deadly brain cancers like glioblastoma and DIPG – 30% complete tumor eradication in pre-clinical models. It outperformed a drug already in Phase 3 trials. Top institutions like Mayo Clinic and Barrow Neurological Institute are backing it with their own funds because they believe in its promise.
If funding stalls now, we lose a breakthrough therapy, a chance to give hope to children and adults facing the most lethal cancers. We lose years of work, collaboration, and momentum. Most of all, we lose lives that could have been saved.
This is why bridging the funding gap isn’t optional – it’s urgent.
CEO & Founder
Mr. Clark is the founder and CEO of Global Cancer Technology Mr. Clark has over 40 years
of medical, financial, and business experience to the Company. Mr. Clarks was the Chairman and CEO of American Radiosurgery; Inc. Mr. Clark specializes in the development and commercialization of medical technologies into going corporate concerns Mr. Clark has purchased technologies and developed patents for various medical applications. Mr. Clark has founded and organized:
-American Radiosurgery produced the first Rotating Gamma Knife radiosurgery device
–Edmonds Medical Systems, Inc. Edmonds was a medical manufacturer of a patented underwater treadmill devices for the orthopedic rehabilitation market.
–Cosmos Medical Technologies is a company that imported European medical laser technologies for development and commercialization in the Western hemisphere.
Chief Scientific Advisor
Dr. Newell’s research broadly involves the following areas of study: the first, studies of how an individual’s immune response genes contribute to infectious and post-infectious chronic inflammatory syndromes, including Post-Traumatic Brain Injury Syndromes, Lyme Disease, Multiple Sclerosis, preeclampsia, and virally induced post-infectious autoimmune syndromes. She is a Professor at Texas A & M and an expert in designing pre-clinical trials.
Medical & Scientific Advisor
Dr. Kesari is a world-renowned board-certified neurologist and neuro-oncologist and is currently Chair, Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute. He is also Director of Neuro-Oncology, Providence Saint John’s Health Center and Member, Los Angeles Biomedical Research Institute. Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd and an internationally recognized scientist and clinician. He is a winner of an Innovation Award by the San Diego Business Journal. He is on the advisory board of American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance. He has been the author of over 250 scientific publications, reviews, or books.
Senior Corporate Advisor
Scientific Advisor
Chief Development Officer
Dr. Thohan is the Chief Development Officer of Global Cancer Technology. He holds MS and PhD degrees in Pharmacology and Toxicology from the University of Arizona and University of Maryland with concentrations in interspecies drug metabolism mechanisms, bioactivation, and systems toxicology.
Sanjeev has extensive experience in Oncology drug discovery, biomarker identification, companion diagnostic identification and drug development from his time at Novartis and Exelixis. He was a Senior Research Fellow in Preclinical/Translational Sciences at the Novartis Institutes for BioMedical Research (NIBR) in the Oncology, Anti-infectives and Cardiovascular medicines therapeutic areas.
Sanjeev has held positions in increasing responsibility covering disciplines of ADME, DMPK and TOX areas of preclinical research with small and large organizations (Walter Reed Army Institute for Research, Covance, AstraZeneca, ViroPharma, Exelixis, Novartis and Xeris).
Sanjeev has advanced 42 molecules from pre-clinical to Phase 1 clinical trials.
